ClinicalTrials.gg
TerminatedNCT02336048Updated Apr 8, 2021

A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities

A Phase 1 interventional study of Chlorambucil and Obinutuzumab in B-Cell Chronic Lymphocytic Leukemia, sponsored by Hoffmann-La Roche. Terminated at 14 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-04-08.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Why this study was terminated
This study was terminated early because premedication with tocilizumab was unlikely to reduce the risk of IRR.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
38
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche — 1 open to participants now, 2 under way, none of them phase 3. Leukemia, Lymphocytic, Chronic, B-Cell · Hoffmann-La Roche.

Enrollment
31st of 36
38 · median 99
Started
2015
with 2 others
Phase 1
8 of 48
1 open now
Registered
38th of 48
by date

Among the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, this one is the 31st largest by enrollment of the 36 interventional ones that give a count, is one of 3 that started in 2015, is one of 8 in phase 1, and was the 38th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

1 of the 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche is open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Leukemia, Lymphocytic, Chronic, B-Cell by Hoffmann-La Roche, or all of them as a file.
02

Study summary

This multicenter, double-blind, randomized, placebo-controlled study will evaluate the safety of a single infusion of tocilizumab versus placebo, administered in addition to standard premedications (antipyretic, antihistamine, and corticosteroid) prior to the first infusion of obinutuzumab administered in combination with oral chlorambucil to participants with previously untreated B-CLL who have comorbidities. All eligible participants will be treated with a total of 6 cycles of obinutuzumab + chlorambucil (cycle length = 28 days).

03

Conditions studied

  • B-Cell Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Documented cluster of differentiation (CD) 20+ B-CLL according to NCI/IWCLL guideline
  • Total Cumulative Illness Rating Scale (CIRS) score greater than (>) 6 and/or less than (\<) 70 milliliters per minute (mL/min)
  • Previously untreated chronic lymphocytic leukemia (CLL) requiring treatment according to NCI/IWCLL guidelines who warrant treatment if they have any of the protocol-specified comorbidities
  • > 6 months
  • Adequate hematological function, unless abnormalities are caused by underlying CLL
  • Agreement to use highly effective measures per protocol

Exclusion criteria

Exclusion Criteria:

  • Any previous CLL treatment
  • Documented transformation of CLL to aggressive non-Hodgkin's lymphoma (Richter's transformation)
  • Abnormal laboratory test values, unless abnormalities are caused by underlying CLL
  • History of progressive multifocal leukoencephalopathy
  • Previous treatment with tocilizumab for any indication
  • History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
  • Known to any of the study drugs
  • History of prior unless the malignancy has been treated with a curative intent or is in remission without treatment for at least (>/=) 5 years prior to enrollment and with the exception of curatively-treated basal squamous cell carcinoma of the skin, low grade in situ carcinoma of the cervix, or low grade early stage localized prostate cancer treated surgically with curative intent and or ductal carcinoma in situ of the breast treated with lumpectomy alone
  • Treatment with at any dose (except topical formulations) during the 2 weeks prior to the start of Cycle 1 Day 1. Regular treatment with glucocorticoids (> 5 days duration) is also prohibited during the 4-week screening period
  • Ongoing treatment with medications or anti-tumor necrosis factor biologic therapies
  • Evidence of significant, uncontrolled concomitant diseases that could affect compliance with this protocol or interpretation of results, including significant cardiovascular or pulmonary disease
  • Known active or history of recurrent bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) requiring treatment with intravenous (IV) antibiotics or hospitalization within 4 weeks prior to the start of Cycle 1 Day 1
  • Active tuberculosis (TB) requiring treatment within 3 years prior to baseline or latent TB diagnosed during screening that has not been appropriately treated
  • Vaccination with live or attenuated vaccines within 28 days prior to start of treatment
  • Major surgery (within 4 weeks prior to Cycle 1 Day 1), other than for diagnosis
  • Positive test results for chronic infection or positivity for hepatitis B core antibody
  • Positive test results for
  • Known history of human immuno-deficiency virus () seropositive status
  • Positive test results for human T-lymphotropic virus 1 (HTLV 1)
  • Pregnant or lactating women
  • Participation in another clinical study with drug intervention unless the last dose administered was greater than 5 half-lives of the study product prior to study start
  • Any participant actively taking anti- medication or any participant who is fully anticoagulated with warfarin, low-molecular weight heparin or a novel oral anticoagulant including dabigatran, rivaroxiban, epixiban, and similar
  • Previous treatment with B-cell depleting agents
  • Any inherited bleeding disorder
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
38 participants (actual)

Study arms

  • Active comparator
    Placebo + Obinutuzumab + Chlorambucil

    Participants will receive placebo and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.

    Drug: Chlorambucil · Drug: Obinutuzumab · Drug: Placebo · Other: Standard Premedication

  • Experimental
    Tocilizumab + Obinutuzumab + Chlorambucil

    Participants will receive tocilizumab and standard premedications on Days 1 and 2 of Cycle 1 (cycle length= 28 days) along with obinutuzumab and chlorambucil administered for 6 cycles.

    Drug: Chlorambucil · Drug: Obinutuzumab · Other: Standard Premedication · Drug: Tocilizumab

Interventions

  • Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.

  • Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.

    Also known as: RO5072759, GA101, Gazya, Gazyvaro

  • DrugPlacebo

    Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).

  • OtherStandard Premedication

    Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).

  • Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).

    Also known as: RO4877533, RoActemra, Actemra

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: Baseline up to approximately 196 days

Secondary outcomes

  1. Percentage of Participants With Infusion-Related Reactions (IRRs) as Assessed by Investigator and Reviewed by Endpoint Adjudication Committee (EAC)

    Time frame: Day 1 (within 24 hours of first obinutuzumab infusion)

  2. Percentage of Participants With IRRs by Severity According to National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.0 (NCI CTCAE v4.0)

    Time frame: Day 1 (within 24 hours of first obinutuzumab infusion)

  3. Percentage of Participants With IRRS >= Grade 3 as assessed by the Investigator and Reviewed by the EAC

    Time frame: Day 1 (within 24 hours of first obinutuzumab infusion)

  4. Number of Interruptions or Administration rate modifications of the First Infusion of Obinutuzumab

    Time frame: Day 1 (within 24 hours of first obinutuzumab infusion)

  5. Percentage of Treatment Discontinuations due to IRR

    Time frame: Day 1 (within 24 hours of first obinutuzumab infusion)

  6. Percentage of Participants With Overall Response as Assessed by Investigator According to NCI/ International Workshop on Chronic Lymphocytic Leukemia (IWCLL) Guidelines

    Time frame: 84 days after last treatment (up to approximately 280 days)

  7. Percentage of Participants With Negative Results for Minimal Residual Disease (MRD) Measured According to NCI/IWCLL Guidelines

    Time frame: 84 days after last treatment (up to approximately 280 days)

  8. Area Under the Serum Concentration-Time Curve From Time Zero to Extrapolated Infinite Time (AUC[0-inf]) of Obinutuzumab

    Time frame: Cycle 1 Day 1 (C1D1), C1D2: Pre-dose (0 hours [hrs]), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1, C6D1: pre-dose (0 hrs); additionally at 3 months after last treatment (9 months) (1 cycle=28 days)

  9. Maximum Observed Serum Concentration (Cmax) of Obinutuzumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1, C6D1: pre-dose (0 hrs); additionally at 3 months after last treatment (9 months) (1 cycle=28 days)

  10. Terminal Half-Life (t1/2) of Obinutuzumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1, C6D1: pre-dose (0 hrs); additionally at 3 months after last treatment (9 months) (1 cycle=28 days)

  11. Area Under the Serum Concentration-Time Curve From Time Zero to Last Quantifiable Concentration (AUC[0-last]) of Obinutuzumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1, C6D1: pre-dose (0 hrs); additionally at 3 months after last treatment (9 months) (1 cycle=28 days)

  12. Total Clearance (CL) of Obinutuzumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1, C6D1: pre-dose (0 hrs); additionally at 3 months after last treatment (9 months) (1 cycle=28 days)

  13. Volume of Distribution (Vd) of Obinutuzumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1, C6D1: pre-dose (0 hrs); additionally at 3 months after last treatment (9 months) (1 cycle=28 days)

  14. AUC(0-inf) of Tocilizumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D1: immediately after tocilizumab infusion (1 hr); C1D3; C1D8, C1D15, C2D1: pre-dose (0 hrs) (1 cycle=28 days)

  15. Cmax of Tocilizumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D1: immediately after tocilizumab infusion (1 hr); C1D3; C1D8, C1D15, C2D1: pre-dose (0 hrs) (1 cycle=28 days)

  16. t1/2 of Tocilizumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D1: immediately after tocilizumab infusion (1 hr); C1D3; C1D8, C1D15, C2D1: pre-dose (0 hrs) (1 cycle=28 days)

  17. AUC(0-last) of Tocilizumab

    Time frame: C1D1, C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D1: immediately after tocilizumab infusion (1 hr); C1D3; C1D8, C1D15, C2D1: pre-dose (0 hrs) (1 cycle=28 days)

  18. Change From Baseline in Interleukin (IL)-6 Level

    1 cycle=28 days

    Time frame: C1D1: pre-dose (0 hrs) (Baseline), immediately after tocilizumab and obinutuzumab infusion (1 hr, approximately 7 hrs); C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1: pre-dose (0 hrs); C1D3

  19. Change From Baseline in Level of Downstream Biomarker of IL-6 Activation: Soluble IL-6 Receptor (sIL-6R)

    1 cycle=28 days

    Time frame: C1D1: pre-dose (0 hrs) (Baseline), immediately after tocilizumab and obinutuzumab infusion (1 hr, approximately 7 hrs); C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1: pre-dose (0 hrs); C1D3

  20. Change From Baseline in Level of Downstream Biomarker of IL-6 Activation: Ferritin

    1 cycle=28 days

    Time frame: C1D1: pre-dose (0 hrs) (Baseline), immediately after tocilizumab and obinutuzumab infusion (1 hr, approximately 7 hrs); C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1: pre-dose (0 hrs); C1D3

  21. Change From Baseline in Level of Downstream Biomarker of IL-6 Activation: C-Reactive Protein (CRP)

    1 cycle=28 days

    Time frame: C1D1: pre-dose (0 hrs) (Baseline), immediately after tocilizumab and obinutuzumab infusion (1 hr, approximately 7 hrs); C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1: pre-dose (0 hrs); C1D3

  22. Change From Baseline in Level of Downstream Biomarker of IL-6 Activation: Soluble Glycoprotein (gp) 130

    1 cycle=28 days

    Time frame: C1D1: pre-dose (0 hrs) (Baseline), immediately after tocilizumab and obinutuzumab infusion (1 hr, approximately 7 hrs); C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1: pre-dose (0 hrs); C1D3

  23. Change From Baseline in Level of Downstream Biomarker of IL-6 Activation: Serum Amyloid A (SAA)

    1 cycle=28 days

    Time frame: C1D1: pre-dose (0 hrs) (Baseline), immediately after tocilizumab and obinutuzumab infusion (1 hr, approximately 7 hrs); C1D2: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D8, C1D15, C2D1: pre-dose (0 hrs); C1D3

  24. Percentage of Participants With Depletion in Absolute Lymphocyte Count (ALC)

    Time frame: C1D1,C1D2,C1D8,C1D15: pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C1D3; C2D1: Pre-dose (0 hrs), immediately after obinutuzumab infusion (approximately 7 hrs); C3D1,C4D1,C5D1,C6D1: pre-dose (0 hrs) (1 cycle=28 days)

07

Study locations

14 sites
  • Carmel medical center
    Haifa, 3436212, Israel
  • Meir Medical Center; Heamatology Dept
    Kfar Saba, 4428164, Israel
  • Kaplan Medical Center; Hematology Institute; Hematolgy Institute
    Rehovot, 7610001, Israel
  • Ziv Medical Center
    Zfat, 1311001, Israel
  • A.O. Universitaria S. Martino Di Genova; Ematologia 1
    Genova, Liguria 16132, Italy
  • Asst Grande Ospedale Metropolitano Niguarda; Dipartimento Di Ematologia Ed Oncologia
    Milano, Lombardia 20162, Italy
  • Ospedale Businco; Ematologia
    Cagliari, Sardegna 09121, Italy
  • Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia; Oncologia Medica
    Sant'Andrea Delle Fratte (PG), Umbria 06132, Italy
  • RECUH, Oncology Centre of Latvia; Clinic of Chemotherapy and Heamatology
    Riga, 1079, Latvia
  • Hospital Universitari Vall d'Hebron; Servicio de Hematologia
    Barcelona, 08035, Spain
  • Hospital Clínic i Provincial; Servicio de Hematología y Oncología
    Barcelona, 08036, Spain
  • Hospital Univ. 12 de Octubre; Servicio de Hematologia
    Madrid, 28041, Spain
  • Hospital Universitario Virgen del Rocio; Servicio de Hematologia
    Sevilla, 41013, Spain
  • Barts & London School of Med; Medical Oncology
    London, EC1A 7BE, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2015 to primary completion in Sep 2018, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 6, 2015
First posted
Jan 12, 2015
StartActual
Jun 26, 2015
Primary completionActual
Sep 21, 2018
CompletionActual
Sep 21, 2018
Last update
Apr 8, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02336048
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 12, 2015
Start date
Jun 26, 2015
Primary completion
Sep 21, 2018
Completion
Sep 21, 2018
Last update
Apr 8, 2021

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion